RxDoctor Payments Data

Christian Lates, MD

Internal Medicine · Elma, NYNPI 1649279191

Payments from drug & device makers

$13,409in general payments, 2019–2025

Across 670 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$762
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$13,24599%
  • Education$1641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,409 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$41,463
Medicare patients
158
Services billed
418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin154$198,468
MounjaroTirzepatide115$135,205
EliquisApixaban129$113,479
FarxigaDapagliflozin Propanediol85$105,680
OzempicSemaglutide81$104,677
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$26,226
TrulicityDulaglutide12$24,250
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$19,731
Synjardy XrEmpagliflozin/Metformin Hcl24$19,467
Soliqua 100-33Insulin Glargine/Lixisenatide15$18,427
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$16,817
Atorvastatin Calcium605$9,324
NexlizetBempedoic Acid/Ezetimibe12$8,612
Fenofibrate16$7,932
LinzessLinaclotide12$7,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat$762$234,753195 claims
Lilly USA, LLCMounjaro, Trulicity$1,138$159,455127 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,495$117,226116 claims
PfizerEliquis$636$113,479129 claims
Novo NordiskOzempic$1,438$104,67781 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$407$29,60843 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$235$18,42715 claims
AbbVieLinzess, Fetzima, Synthroid$1,241$16,85763 claims
Esperion Therapeutics, Inc.Nexlizet$618$8,61212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Elma

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →